Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$11.7M |
| 2 |
Jack in the Box
JACK
|
+$10M |
| 3 |
CVSA
Covista Inc
CVSA
|
+$9.81M |
| 4 |
POSH
Poshmark, Inc. Class A Common Stock
POSH
|
+$6.39M |
| 5 |
VMW
VMware, Inc
VMW
|
+$6.22M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dollar Tree
DLTR
|
+$5M |
| 2 |
CIVI
Civitas Resources
CIVI
|
+$4.58M |
| 3 |
Alibaba
BABA
|
+$4.31M |
| 4 |
Centene
CNC
|
+$4.16M |
| 5 |
Prudential Financial
PRU
|
+$3.94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.78% |
| 2 | Consumer Discretionary | 12.04% |
| 3 | Healthcare | 11.59% |
| 4 | Financials | 10.04% |
| 5 | Materials | 9.14% |
Similar funds
Invenomic Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Invenomic Capital Management held 170 positions worth $468M, up 52% from $308M the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Invenomic Capital Management deployed $174M of net new capital in Q4 2021, opening 51 new positions and adding to 61 existing holdings. Its largest new stake was AT&T: 626,014 shares worth $11.6M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 7.4% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Civitas Resources, an estimated $4.58M trimmed.
- Invenomic Capital Management's largest Q4 2021 buy was AT&T: 626,014 shares worth $11.6M.
- Invenomic Capital Management added most to Cigna in Q4 2021, an estimated $5.95M increase.
- Invenomic Capital Management's biggest Q4 2021 reduction was Civitas Resources, cutting an estimated $4.58M.
- Invenomic Capital Management fully exited Dollar Tree in Q4 2021, selling an estimated $5M.
- Invenomic Capital Management's ten largest holdings make up 26% of its $468M portfolio in Q4 2021.
- Invenomic Capital Management opened 51 new positions and closed 28 in Q4 2021.
- Invenomic Capital Management's portfolio value rose 52% quarter-over-quarter to $468M.
Based on Invenomic Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.